Testing several drugs for tumors caused by NF2-related schwannomatosis
Official title: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests several drugs in people whose NF2 tumors are growing.
Read our full plain-language summary
What the trial team says
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. * Investigational Drug Sub-study A: Brigatinib * Investigational Drug Sub-study B: Neratinib * Investigational Drug Sub-study C: Retifanlimab plus bevacizumab
Key facts
- Registry number
- NCT04374305
- Stage of testing
- Phase 2
- Conditions studied
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
Where it is running
This trial lists 6 sites.
-
California
- UCLA Medical Center (Los Angeles)
-
Florida
- University of Miami (Miami)
-
Indiana
- Indiana University School of Medicine (Indianopolis)
-
Maryland
- Johns Hopkins Hospital (Baltimore)
-
Massachusetts
- Massachusetts General Hospital (Boston)
-
New York
- New York University Langone Medical Center (New York)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.